Two-Antibody Staining Method, A Cost-Saving Strategy for Universal Lynch Syndrome Screening in Endometrial Cancers

Natthakrit  Anansitthikorn; Suchanan  Hanamornroongruang

doi:10.33192/Smj.2022.14

Authors

Natthakrit Anansitthikorn Department of Pathology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok
Suchanan Hanamornroongruang Department of Pathology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok

DOI:

https://doi.org/10.33192/Smj.2022.14

Keywords:

Endometrial carcinoma, lynch syndrome, MMR proteins, MSH2 loss

Abstract

Objective: Lynch syndrome is an autosomal dominant disorder that increases the risk of cancers in many sites. In women, endometrial cancer is often a sentinel tumor and thus immunohistochemistry for mismatch repair (MMR) proteins MLH1, MSH2, MSH6 and PMS2 is encouraged as a screening test. To reduce cost, staining for only 2 MMR proteins PMS2 and MSH6 has been proposed. This study aimed to determine whether a 2-antibody staining test is enough to screen for Lynch syndrome in endometrial cancer patients.
Materials and Methods: Cases of endometrial carcinoma with immunohistochemistry for 4 MMR proteins were reviewed. Results of immunohistochemistry screening were compared between all four antibodies and only two (PMS2 and MSH6) antibodies.
Results: Loss of expression of any MMR proteins was detected in 51 out of 203 cases (25.12%). Twenty-three cases (45%) showed loss of MLH1 and PMS2; 13 cases (25%) showed loss of MSH2 and MSH6; five cases (10%) showed loss of MSH6; seven cases (14%) showed loss of PMS2 and three cases (6%) showed loss of MSH2. The 2-antibody method detected 48 cases (94%) with a MMR deficiency but failed to detect three cases (6%) with an isolate loss of MSH2. The screening results from the 2-antibody method are 98.5% (200/203) in accordance with the original 4-antibody method.
Conclusion: The 2-antibody method is a quite effective option to screen for Lynch syndrome in endometrial cancers. However, MSH2 mutations may be missed in a few cases.

References

Ryan NA, McMahon RF, Ramchander NC, Seif MW, Evans DG, Crosbie EJ. Lynch syndrome for the gynaecologist. Obstet

Gynaecol. 2021;23(1):9-20.

Mills AM, Liou S, Ford JM, Berek JS, Pai RK, Longacre TA. Lynch syndrome screening should be considered for all patients with

newly diagnosed endometrial cancer. Am J Surg Pathol. 2014;38(11):1501-9.

Meyer LA, Broaddus RR, Lu KH. Endometrial cancer and Lynch syndrome: clinical and pathologic considerations. Cancer Control. 2009;16(1):14-22.

Backes FJ, Leon ME, Ivanov I, Suarez A, Frankel WL, Hampel H, et al. Prospective evaluation of DNA mismatch repair protein expression in primary endometrial cancer. Gynecol Oncol. 2009;114(3):486-90.

Ryan NAJ, McMahon R, Tobi S, Snowsill T, Esquibel S, Wallace AJ, et al. The proportion of endometrial tumours associated with Lynch syndrome (PETALS): A prospective cross-sectional study. PLoS Med. 2020;17(9):e1003263.

Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med. 2005;352(18): 1851-60.

Egoavil C, Alenda C, Castillejo A, Paya A, Peiro G, Sanchez- Heras AB, et al. Prevalence of Lynch syndrome among patients with newly diagnosed endometrial cancers. PLoS One. 2013;8(11):e79737.

Manchana T, Ariyasriwatana C, Triratanachat S, Phowthongkum P. Lynch Syndrome in Thai Endometrial Cancer Patients. Asian Pac J Cancer Prev. 2021;22(5):1477-83.

Mehta A, Gupta, G. Lynch syndrome-It’s time we start detecting it. J Curr Oncol. 2018;1:55-60.

Watkins JC, Yang EJ, Muto MG, Feltmate CM, Berkowitz RS, Horowitz NS, et al. Universal Screening for Mismatch-Repair Deficiency in Endometrial Cancers to Identify Patients With Lynch Syndrome and Lynch-like Syndrome. Int J Gynecol Pathol. 2017;36(2):115-27.

Lu KH, Dinh M, Kohlmann W, Watson P, Green J, Syngal S, et al. Gynecologic cancer as a “sentinel cancer” for women with hereditary nonpolyposis colorectal cancer syndrome. Obstet Gynecol. 2005;105(3):569-74.

Garg K, Leitao MM, Jr., Kauff ND, Hansen J, Kosarin K, Shia J, et al. Selection of endometrial carcinomas for DNA mismatch repair protein immunohistochemistry using patient age and tumor morphology enhances detection of mismatch repair abnormalities. Am J Surg Pathol. 2009;33(6):925-33.

Crosbie EJ, Ryan NAJ, Arends MJ, Bosse T, Burn J, Cornes JM, et al. The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome. Genet Med. 2019;21(10):2390-400.

Cho KR, Cooper K, Croce S, Djordevic B, Herrington S, Howitt B, et al. International Society of Gynecological Pathologists (ISGyP) Endometrial Cancer Project: Guidelines From the Special Techniques and Ancillary Studies Group. Int J Gynecol Pathol. 2019;38 Suppl 1:S114-S22.

Shia J, Tang LH, Vakiani E, Guillem JG, Stadler ZK, Soslow RA, et al. Immunohistochemistry as first-line screening for detecting colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: a 2-antibody panel may be as predictive as a 4-antibody panel. Am J Surg Pathol. 2009;33(11):1639-45.

Hall G, Clarkson A, Shi A, Langford E, Leung H, Eckstein RP, et al. Immunohistochemistry for PMS2 and MSH6 alone can replace a four antibody panel for mismatch repair deficiency screening in colorectal adenocarcinoma. Pathology. 2010;42(5):409-13.

Mojtahed A, Schrijver I, Ford JM, Longacre TA, Pai RK. A twoantibody mismatch repair protein immunohistochemistry screening approach for colorectal carcinomas, skin sebaceous tumors, and gynecologic tract carcinomas. Mod Pathol. 2011;24(7):1004-14.

Crim AK, Perkins, V.B., Husain, S., Ding, K., Holman, L.L. Feasibility of two-antibody vs four-antibody mismatch repair protein immunohistochemistry as initial screening for Lynch syndrome in patients with endometrial adenocarcinoma. Gynecol Oncol. 2017;145(1):44.

Ryan N, Wall J, Crosbie EJ, Arends M, Bosse T, Arif S, et al. Lynch syndrome screening in gynaecological cancers: results of an international survey with recommendations for uniform reporting terminology for mismatch repair immunohistochemistry results. Histopathology. 2019;75(6):813-24.

Modica I, Soslow RA, Black D, Tornos C, Kauff N, Shia J. Utility Anansitthikorn et al. https://he02.tci-thaijo.org/index.php/sirirajmedj/index Volume 74, No.2: 2022 Siriraj Medical Journal 113 Original Article SMJ of immunohistochemistry in predicting microsatellite instability

in endometrial carcinoma. Am J Surg Pathol. 2007;31(5):744-51.

Long Q, Peng Y, Tang Z, Wu C. Role of endometrial cancer abnormal MMR protein in screening Lynch-syndrome families. Int J Clin Exp Pathol. 2014;7(10):7297-303.

Puangsricharoen P, Manchana, T., Ariyasriwatana, C., Triratanachat, S. Immunohistochemistry staining for the mismatch repair proteins in endometrial cancer patients. Thai journal of obstetrics and gynaecology. 2020;28:79-85.

Pearlman R, Markow M, Knight D, Chen W, Arnold CA, Pritchard CC, et al. Two-stain immunohistochemical screening for Lynch syndrome in colorectal cancer may fail to detect mismatch repair deficiency. Mod Pathol. 2018;31(12):1891-900.